Evaluating MRI's ability to predict response to Optune therapy in glioblastoma patients
Assessment of Optune Therapy for Patients with Newly Diagnosed Glioblastoma Using Advanced MRI
This study is testing if advanced MRI scans can help doctors predict how well glioblastoma patients will respond to Optune therapy combined with chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical College of Wisconsin Academic / other |
| Drugs / interventions | bevacizumab, chemotherapy |
| Locations | 1 site (Milwaukee, Wisconsin) |
| Trial ID | NCT03297125 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of standard versus advanced MRI techniques in predicting patient responses to Optune therapy for newly diagnosed glioblastoma. Patients will undergo both types of MRI while receiving adjuvant chemotherapy alongside Optune treatment. The study seeks to establish reliable evaluation methods that could optimize treatment regimens and improve patient outcomes. By analyzing the data, researchers hope to identify which patients are most likely to benefit from this innovative therapy.
Who should consider this trial
Good fit: Ideal candidates are individuals with newly diagnosed glioblastoma (WHO grade IV) who are eligible for Optune therapy.
Not a fit: Patients with a history of significant skull defects or those with low Karnofsky Performance Status may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment personalization for glioblastoma patients, leading to improved survival rates and quality of life.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques to evaluate treatment responses, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed glioblastoma (GBM), World Health Organization (WHO) grade IV. Exclusion Criteria: * Optune compliance \< 75%; they would be excluded from the final analyses. * History of craniectomy or significant skull defect (contraindication to Optune). * Active implantable medical device (e.g., deep brain stimulator (DBS), spinal cord stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt). * Karnofsky Performance Status (KPS) \< 60.
Where this trial is running
Milwaukee, Wisconsin
- Froedtert Hospital & Medical College of Wisconsin — Milwaukee, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Jennifer Connelly, MD — Medical College of Wisconsin
- Study coordinator: Cathy Marszalkowski
- Email: cmars@mcw.edu
- Phone: 414-955-1183
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.